Anika Therapeutics (ANIK) Tops Q2 EPS by 10c, Beats on Revenue; Offers FY24 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Anika Therapeutics (ANIK) Tops Q2 EPS by 10c, Beats on Revenue; Offers FY24 Revenue Guidance

Anika Reports Second Quarter 2024 Financial Results

August 8, 2024 4:06 PM EDT

Expanded Regenerative Solutions portfolio with full market release of the Integrity Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating significant market demand

Delivered revenue in line with expectations with 15% adjusted EBITDA margins; Strong first half 2024 international OA Pain Management revenue growth of 17%

Enhanced capital allocation strategy with new $40 million share repurchase program announced in May 2024; Continuing to optimize spending to support HA-based OA Pain Management and Regenerative Solutions growth

BEDFORD, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) --... More